The most-cited record in this corpus, US8106022B2, covers carbohydrate conjugates as delivery agents for oligonucleotides and has been cited 1,093 times, making it the closest thing to a foundational reference in the field. A related family, WO2009073809A2, covers the same subject matter and carries 750 citations. Both sit among a small group of highly cited filings that any new entrant's freedom-to-operate review should check first, since later conjugate patents tend to build on the linker and ligand chemistry these establish.

Filing volume peaked at 362 in 2022 and has since roughly held steady rather than kept climbing — 2021's 329 filings compare to 324 in 2024, a -2% change over that span, which is the last window with complete publication data. Figures for 2025 and 2026 in the raw trend look lower still, but that reflects the roughly 18-month lag between filing and publication rather than an actual drop-off. Treat the field as mature and steady rather than either booming or shrinking.

Fairly concentrated at the top: the five leading assignees together hold 1,363 of the 4,250 records in scope, or 32.1%, and the top ten extend that to 43.9%. Below that the ranking of 100 assignees thins out quickly into single- and double-digit filers, including university groups and specialty-conjugate startups. A new entrant should expect to negotiate around or design around the leader's estate specifically, since it alone accounts for far more records than the next several competitors combined.

Standard GalNAc conjugation relies on the asialoglycoprotein receptor, which is highly expressed on hepatocytes, so the chemistry is inherently liver-biased. Extrahepatic delivery claims in this corpus address the harder problem of routing the same or related conjugates to tissues outside the liver, which typically requires different targeting ligands, altered valency, or conjugation chemistry tuned for a different receptor or uptake mechanism. This is one of the lighter-filed branches relative to the core hepatocyte-targeting claims, based on the IPC composition in this dataset.

The basic GalNAc-ASGPR targeting chemistry is well covered by early, heavily cited filings, so more recent applications — such as US20240307545A1's saponin-oligonucleotide-GalNAc conjugate — tend to claim additional functional elements layered on top, like escape-enhancing moieties or specific linker architectures. These second-wave claims are narrower and mechanism-specific rather than covering the ligand itself. Reviewing what a specific claim actually recites, rather than assuming a general GalNAc patent blocks it, is the practical way to assess exposure here.